Eye Bank Association of India , more than 1,00,000 corneal transplants are required annually , but only 25000 are actually done . Dr Virender Sangwan , Director of Innovation , Dr Shroff ’ s Charity Eye Hospital said , “ Unfortunately , 40 % of the donated corneas do not meet the standards for the transplant . The fact that our supply of corneas is dependent on donors is our biggest challenge .”
French Embassy in India & Biomérieux hold symposium on AMR
The French Embassy in India , and Biomérieux India co-organized the one-day symposium titled “ Antimicrobial Stewardship : Improved Diagnosis for Better Management .” The symposium took place at the Embassy of France to India in New Delhi . Emmanuel Lebrun-Damiens , Counsellor for Education , Science and Culture – French Embassy said : “ France and India are two leaders on global health , and the cooperation between them on Antimicrobial Resistance is very important . 20 % of the Indo-French Centre for the Promotion of Advanced Research ( CEFIPRA ) endowment provides funding for scientific projects in the fields of life science and health ”.
Antimicrobial resistance poses a significant threat to global health , food security , and development . In an effort to combat this pressing issue , the symposium aims to identify and promote best practices and advocacy for avoiding AMR . WHO reports that approximately 700,000 people die each year from bacterial infections in the world .
India ’ s first mRNA based Omicronspecific booster vaccine from Gennova gets DCGI approval
Gennova Biopharmaceuticals , a Pune based company has announced that its mRNA COVID-19 booster vaccine – GEMCOVAC ® -OM – against the Omicron variant of SARS-CoV-2 received Emergency Use Authorization ( EUA ) from the office of the Drugs Controller General of India ( DCGI ). GEMCOVAC ® -OM is the first booster COVID-19 vaccine developed in India against the highly transmissible Omicron variant . GEMCOVAC ® -OM has demonstrated robust immune responses in the phase 3 clinical trial conducted at 20 centers across 13 cities in India In Phase-II / III trials , approximately 3000 individuals received GEMCOVAC-OM and the vaccine was safe and well tolerated .
BioTech
BIOVOICENEWS . COM 09